Document is current
Any future updates will be listed below
-
Authors
Bagnalasta, Matteo https://orcid.org/0009-0002-3566-5179
Mazzaglia, Stefania
De Nile, Maria Chiara
Romanò, Chiara
Pitoni, Giovanna
Phillips, Alice
Amato, Gaetano
Spreafico, Carlo
Morosi, Carlo
Cascella, Tommaso
Marchianò, Alfonso
Maspero, Marianna
Bellia, Valentina
Aliberti, Gianluca
Alessi, Alessandra
Mazzaferro, Vincenzo https://orcid.org/0000-0002-4013-8085
Maccauro, Marco https://orcid.org/0000-0003-1389-3250
Chiesa, Carlo https://orcid.org/0000-0003-0634-013X
-
Funding
Funding for this research was provided by:
Boston Scientific Corporation
- License Information
-
More Information
Article History
Received: 10 February 2025
Accepted: 19 April 2025
First Online: 21 May 2025
Declarations
:
: The study was conducted following the Declaration of Helsinki. It was approved by the local Ethical Committee and by the General Manager of the National Cancer Institute of Milan (INT) with name and number NumberDose in TARE, INT 154/19.
: All patients provided written informed consent for TARE. Italian law does not require informed consent for retrospective data collection in Institute for Research and Care with Scientific Character (IRCCS) as our Institute is.
: Matteo Bagnalasta, Stefania Mazzaglia and Chiara Romanò were supported thanks to grants provided by Boston Scientific.Carlo Spreafico, Vincenzo Mazzaferro, Marco Maccauro and Carlo Chiesa received honoraria as speaker from Boston Scientific. Marco Maccauro and Carlo Chiesa received also honoraria from Terumo and Novartis for the same role.Carlo Chiesa received the grant by Boston Scientific for the present study.The other authors do not report any conflict of interest.
